ArticleClinical advances in periodontics2025
Root coverage using recombinant human fibroblast growth factor-2 treated connective tissue graft: Case studies.
Article in Clinical advances in periodontics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Root coverage using recombinant human fibroblast growth factor-2 treated connective tissue graft: Case studies.Clinical advances in periodontics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis case study documents the application of connective tissue graft (CTG) combined with biologics on treating challenging gingival recession cases of mandibular anterior teeth caused by orthodontic tooth movement.
methodsThree patients presented for periodontal consultation due to gingival recession resulting from orthodontic treatment. The patients reported esthetic concerns and discomfort while brushing their teeth. The gingival defects were mainly localized to the mandibular incisors, with recession depths ranging from 1 to 5 mm and complicated by loss of papilla and a lack of keratinized tissue. RT2 gingival recession with thin gingival phenotype was confirmed. All gingival defects were managed using recombinant human fibroblast growth factor-2 (rhFGF-2) treated CTG. The recipient sites were prepared using tunnel or modified tunnel techniques. CTG harvested from the hard palate was treated with rhFGF-2 for 3 min then inserted into the prepared tunnel space and secured with a sling suture technique for coronal advancement.
resultsThe three patients were followed from 6 months to 6 years. Generally, initial wound healing was within normal limits during the first several weeks. The recession defects were successfully covered, achieving a nearly 100% root coverage rate. The combination of CTG+rhFGF-2 resulted in satisfying recession depth reduction, papilla augmentation, and gain of keratinized tissue. Patients were satisfied with the improvement of esthetics and function.
conclusionsThis innovative approach demonstrates that rhFGF-2 treated CTG significantly improves the mucogingival problems caused by orthodontic treatment. Successful phenotype modification provides functional and esthetic improvement as well as long-term stability of periodontal health. PLAIN LANGUAGE SUMMARY: Receding gums are a common complication after wearing dental braces, which sometimes can be severe if the initial gum tissue is thin. This complication could cause tooth sensitivity, discomfort when brushing, and compromised esthetics. To regenerate the lost tissue, a connective tissue graft (CTG) harvested from the roof of the oral cavity is very commonly used as a transplantation option with substantial supporting evidence. However, for cases of severe gum recession, CTGs still have limitations on treatment. Therefore, clinicians and researchers are dedicated to improving treatment outcomes by adding biomaterials to the graft to enhance clinical outcomes. A relatively new material, recombinant human fibroblast growth factor-2 (rhFGF-2), has proven to be effective in periodontal regenerative treatments and could potentially augment the soft tissue regenerative capacity of the graft. This case study documents the application of rhFGF-2 in combination with CTGs for treating severe gum recession in three patients. The treatment results demonstrate significant improvements with follow-up data ranging from 6 months to 6 years. These improvements include the coverage of exposed root surfaces, regeneration of tissue between teeth, and thickening of gum tissue. Patients were satisfied with the positive changes in function and esthetics resulting from this approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.